Deciphera Pharmaceuticals Inc

NASDAQ:DCPH   3:59:53 PM EDT
8.16
-0.32 (-3.77%)
Products

Deciphera Pharmaceuticals Inc - Launch Of Qinlock® In Germany Underway Transition To Post-Approval Paid Access Program In France Expected In 1H 2022

Published: 01/10/2022 12:29 GMT
Deciphera Pharmaceuticals Inc (DCPH) - Deciphera Pharmaceuticals Inc - Launch of Qinlock® in Germany Underway; Transition to Post-approval Paid Access Program in France Expected in 1h 2022.
Deciphera Pharmaceuticals Inc - Pivotal Phase 3 Motion Study of Vimseltinib in Tgct Patients Underway; Updated Phase 1/2 Data Expected in 2h 2022.
Deciphera Pharmaceuticals Inc - Phase 1 Dose Escalation Data for Dcc-3116 Expected in 2h 2022.
Deciphera Pharmaceuticals Inc - New Pan-raf Research Program Disclosed; Development Candidate Expected in 2022.